Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP ... - The Lancet

Genaro Donaro Urology Reply December 03, 2023

Post a Comment

Buscar

Noticias